Numerous pro-life organizations and leaders have signed a coalition letter addressed to Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary on May 14, 2025, expressing gratitude for their efforts to protect American health and urging action to address the risks associated with the abortion pill, mifepristone. Citing data from the largest ever real-world analysis from the Ethics and Public Policy Center, the letter highlights that 94,605 out of 865,727 women who underwent chemical abortions experienced serious adverse events, such as sepsis, infection, or hemorrhage, at a rate of nearly 11%—22x times higher than the FDA’s reported rate. The letter criticizes the FDA under previous administrations for removing critical safety measures, including Risk Evaluation and Mitigation Strategy (REMS) reporting requirements, in-person provider visits to screen for conditions like ectopic pregnancies, follow-up appointments, and the necessity of physician involvement, arguing these changes have endangered women by prioritizing political motives over scientific evidence.
The letter calls on the FDA to prioritize women’s safety by reinstating previous protections for mifepristone prescriptions and thoroughly reviewing data that suggests the drug is neither safe nor effective. It emphasizes the FDA’s core mission to ensure the safety, efficacy, and security of medical products, asserting that the agency’s credibility and the health of American women depend on addressing the documented harms of mifepristone.
Read the full letter below:
FDA-Coalition-Letter-FINAL
